Optimizing Proficiency for Treating Advanced Soft Tissue Sarcoma

An educational enduring online activity provided by i3 Health has demonstrated knowledge gains regarding the best treatment and management of advanced soft tissue sarcoma. Soft tissue sarcomas are a heterogeneous group of malignancies that arise primarily from the mesodermal tissues of the extremities, trunk and retroperitoneum, and head and neck. The American Cancer Society estimated that 13,190 new cases will be diagnosed in the United States in 2022, and 5,130 of these cases are estimated to ...

Continue reading

Addressing Gaps in Knowledge of Best Practices in Metastatic Triple-Negative Breast Cancer

Of all women diagnosed with cancer in the United States, 30% have breast cancer, which is the second-leading cause of cancer death in this group. Many women have benefitted from regular screening as well as earlier and improved treatment; however, 6% of women present with metastatic disease, and 30% with no initial lymph node involvement will develop metastatic disease. Women with metastatic breast cancer have a poorer prognosis than the overall population of breast cancer patients, and research...

Continue reading

Knowledge Gaps Identified in Treating Recurrent Ovarian Cancer With PARP Inhibitors

As the number of treatments for recurrent ovarian cancer expands, confusion may develop over which therapeutic strategy is best to use. Numerous patient factors need to be taken into account when deciding on a treatment plan, such as patient health status, predictive/prognostic markers, disease-free interval, number of lines and agents used previously, toxicities remaining from previous lines of therapy, and the extent of disease relapse. The new research constantly being conducted creates anoth...

Continue reading

Survey of Oncology Nurses Reveals Knowledge Gaps Surrounding Biosimilars

A biosimilar is a biological agent that is very much like another previously FDA-approved biological agent, called the reference drug. Biosimilars and their reference drugs are both made from living organisms, but they may be made in different ways and of slightly different substances. A biosimilar must demonstrate the same safety and efficacy and work in the same way as the reference drug, and it must also be used in the same way, at the same dose, and for the same condition. There are currentl...

Continue reading

Knowledge Gaps Surrounding CRPC Risk Assessment, Treatment

Over the past few years, the treatment options for castration-resistant prostate cancer (CRPC) have increased to include novel hormone therapies, second-generation taxanes, immunotherapy, and bone-targeted and bone metastasis-targeted agents. Due to an absence of large prospective trials, clinical decision making needs to be based on many different factors, including optimal treatment sequences and combinations, patient health status (eg, asymptomatic or symptomatic), rate of disease progression...

Continue reading

Educational Need in Castration-Resistant Prostate Cancer

Due to the increase in treatment options for castration-resistant prostate cancer (CRPC) in recent years, some confusion exists over the optimal therapeutic approach. A number of factors must be considered in CRPC treatment, including patient health status, rate of disease progression and disease burden, presence of bone or visceral metastases, mechanism of action and tolerability of available agents, and prior lines of therapy and response. Baseline data collected from i3 Health's continuing me...

Continue reading

Knowledge Gaps in the Treatment of Carcinoid Syndrome

Optimal management of carcinoid syndrome in patients with neuroendocrine tumors poses a challenge, due to the fact that the primary symptoms of carcinoid syndrome are associated with more common diseases. Because timely recognition is difficult, symptoms of carcinoid syndrome can negatively impact patients' quality of life and functioning. Baseline data collected from a continuing nursing education (CNE)-approved Oncology Nursing Strategy Session titled Optimizing Management of Carcinoid Syndrom...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.